Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. 2001

T Kakinuma, and K Nakamura, and M Wakugawa, and H Mitsui, and Y Tada, and H Saeki, and H Torii, and A Asahina, and N Onai, and K Matsushima, and K Tamaki
Department of Dermatology, Faculty of Medicine, and the Department of Molecular Preventive Medicine, University of Tokyo, Tokyo, Japan.

BACKGROUND Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease characterized by the predominant infiltration of TH2-type cells in lesional skin. Thymus and activation-regulated chemokine (TARC/CCL17) is a chemokine that attracts CC chemokine receptor 4-positive (CCR4+) or CCR8+ cells. OBJECTIVE The purpose of this study was to investigate the participation of TARC in AD. METHODS We measured serum TARC levels in 40 patients with AD, 20 healthy control subjects, and 20 patients with psoriasis. We also examined disease activity by using SCORAD score; serum soluble E-selectin, soluble IL-2 receptor, IgE, and GM-CSF levels; and eosinophil numbers in peripheral blood, as well as correlations between TARC levels and these factors. The positivity of CCR4 of CD4+CD45RO+ cells in PBMCs was examined by using FACS analysis. Immunohistochemical staining of TARC and GM-CSF was performed in the lesional skin of patients with AD. RESULTS The serum TARC levels of patients with AD were significantly higher than those of healthy control subjects and patients with psoriasis. The serum TARC levels significantly correlated with eosinophil number (r = 0.61), SCORAD score (r = 0.60), and serum soluble E-selectin levels (r = 0.58) and weakly correlated with serum soluble IL-2 receptor levels (r = 0.34) in patients with AD. The TARC levels of patients with AD decreased after the treatment in accordance with the improvement of clinical symptoms. The CCR4 positivity of CD4+CD45RO+ cells in PBMCs of patients with AD was also higher than that of healthy control subjects. Immunohistochemical staining revealed that TARC was positive in keratinocytes in the epidermis and in vascular endothelial cells, T cells, and dendritic cells in the dermis. CONCLUSIONS Serum TARC levels are associated with disease activity of AD, and TARC may play an important role in the pathogenesis of AD.

UI MeSH Term Description Entries
D007073 Immunoglobulin E An immunoglobulin associated with MAST CELLS. Overexpression has been associated with allergic hypersensitivity (HYPERSENSITIVITY, IMMEDIATE). IgE
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D003876 Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema. Eczema, Atopic,Eczema, Infantile,Neurodermatitis, Atopic,Neurodermatitis, Disseminated,Atopic Dermatitis,Atopic Eczema,Atopic Neurodermatitis,Disseminated Neurodermatitis,Infantile Eczema
D004804 Eosinophils Granular leukocytes with a nucleus that usually has two lobes connected by a slender thread of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and stainable by eosin. Eosinophil
D006634 Histamine H1 Antagonists Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. Antihistamines, Classical,Antihistaminics, Classical,Antihistaminics, H1,Histamine H1 Antagonist,Histamine H1 Receptor Antagonist,Histamine H1 Receptor Antagonists,Histamine H1 Receptor Blockaders,Antagonists, Histamine H1,Antagonists, Histamine H1 Receptor,Antihistamines, Sedating,Blockaders, Histamine H1 Receptor,First Generation H1 Antagonists,H1 Receptor Blockaders,Histamine H1 Blockers,Receptor Blockaders, H1,Antagonist, Histamine H1,Classical Antihistamines,Classical Antihistaminics,H1 Antagonist, Histamine,H1 Antagonists, Histamine,H1 Antihistaminics,Sedating Antihistamines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000305 Adrenal Cortex Hormones HORMONES produced by the ADRENAL CORTEX, including both steroid and peptide hormones. The major hormones produced are HYDROCORTISONE and ALDOSTERONE. Adrenal Cortex Hormone,Corticoid,Corticoids,Corticosteroid,Corticosteroids,Cortex Hormone, Adrenal,Hormone, Adrenal Cortex,Hormones, Adrenal Cortex

Related Publications

T Kakinuma, and K Nakamura, and M Wakugawa, and H Mitsui, and Y Tada, and H Saeki, and H Torii, and A Asahina, and N Onai, and K Matsushima, and K Tamaki
September 2022, Allergy and asthma proceedings,
T Kakinuma, and K Nakamura, and M Wakugawa, and H Mitsui, and Y Tada, and H Saeki, and H Torii, and A Asahina, and N Onai, and K Matsushima, and K Tamaki
May 2018, The Journal of dermatology,
T Kakinuma, and K Nakamura, and M Wakugawa, and H Mitsui, and Y Tada, and H Saeki, and H Torii, and A Asahina, and N Onai, and K Matsushima, and K Tamaki
March 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
T Kakinuma, and K Nakamura, and M Wakugawa, and H Mitsui, and Y Tada, and H Saeki, and H Torii, and A Asahina, and N Onai, and K Matsushima, and K Tamaki
September 2002, Veterinary immunology and immunopathology,
T Kakinuma, and K Nakamura, and M Wakugawa, and H Mitsui, and Y Tada, and H Saeki, and H Torii, and A Asahina, and N Onai, and K Matsushima, and K Tamaki
March 2014, The Journal of dermatology,
T Kakinuma, and K Nakamura, and M Wakugawa, and H Mitsui, and Y Tada, and H Saeki, and H Torii, and A Asahina, and N Onai, and K Matsushima, and K Tamaki
May 2005, Allergy,
T Kakinuma, and K Nakamura, and M Wakugawa, and H Mitsui, and Y Tada, and H Saeki, and H Torii, and A Asahina, and N Onai, and K Matsushima, and K Tamaki
December 2020, Veterinary dermatology,
T Kakinuma, and K Nakamura, and M Wakugawa, and H Mitsui, and Y Tada, and H Saeki, and H Torii, and A Asahina, and N Onai, and K Matsushima, and K Tamaki
December 2014, Journal of the American Academy of Dermatology,
T Kakinuma, and K Nakamura, and M Wakugawa, and H Mitsui, and Y Tada, and H Saeki, and H Torii, and A Asahina, and N Onai, and K Matsushima, and K Tamaki
May 2004, Journal of dermatological science,
T Kakinuma, and K Nakamura, and M Wakugawa, and H Mitsui, and Y Tada, and H Saeki, and H Torii, and A Asahina, and N Onai, and K Matsushima, and K Tamaki
September 2023, Journal of the European Academy of Dermatology and Venereology : JEADV,
Copied contents to your clipboard!